Format

Send to

Choose Destination
Clin Toxicol (Phila). 2015;53(7):624-8. doi: 10.3109/15563650.2015.1054502. Epub 2015 Jun 11.

NBOMe and 2C substitute phenylethylamine exposures reported to the National Poison Data System.

Author information

1
Rocky Mountain Poison & Drug Center, Denver Health and Hospital Authority , Denver, Colorado , USA.

Abstract

BACKGROUND:

Hallucinogenic designer drugs, especially NBOMe and the 2C substitute phenylethylamine series, have been increasing ubiquitous in past years. The purpose of this study is to characterize and compare clinical features of NBOMe and 2C exposures in humans.

METHOD:

This is a retrospective cohort study of all single agent exposures to NBOMe and 2C substitute phenylethlamine reported to the National Poison Data System (NPDS) from 1st September 2012 to 30th September 2014.

RESULTS:

Over the study period, there were a total 341 cases including 148 NBOMe exposures and 193 2C exposures. The majority cases involved men (73.9%); median age was 18 years (Interquartile-range, 16-21). Similar clinical effects were reported in both groups including tachycardia (45.2%), agitation/irritable (44.3%), hallucination/delusion (32.0%), confusion (19.1%) and hypertension (18.5%). There were higher incidences of hallucination/delusion, single episode seizure and benzodiazepine administration in NBOMe exposures (40.5%, 8.8% and 50.0%respectively) than those of 2C exposures (25.4%, 3.1%, and 32.6% respectively). There were 2.3% death; no difference between two groups.

DISCUSSION:

The higher rate of symptoms in NBOMe is consistent with the higher 5HT2A agonistic effects of NBOMe described in both molecular and animal studies.

CONCLUSION:

Common clinical effects of NBOMe and 2C exposures were tachycardia, agitation/irritable, hallucination/delusion, confusion, and hypertension. There were higher incidences of hallucination/delusion, single episode seizure and benzodiazepine administration in NBOMe.

KEYWORDS:

2C; NBOMe; Substitute phenylethylamine

PMID:
26065360
DOI:
10.3109/15563650.2015.1054502
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center